COVID-19 and myotonic dystrophy: Case reports and systematic review.
| Autor: | Mazzitelli M; Infectious and Tropical Diseases Unit, Padua Hospital, Padua, Italy., Trevenzoli M; Infectious and Tropical Diseases Unit, Padua Hospital, Padua, Italy., Brundu M; Infectious and Tropical Diseases Unit, Padua Hospital, Padua, Italy., Squarzoni G; Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy., Cattelan AM; Infectious and Tropical Diseases Unit, Padua Hospital, Padua, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of infection in developing countries [J Infect Dev Ctries] 2023 Feb 28; Vol. 17 (2), pp. 182-187. Date of Electronic Publication: 2023 Feb 28. |
| DOI: | 10.3855/jidc.15653 |
| Abstrakt: | Introduction: Steinert's disease is a rare genetic disorder characterized by progressive myotonia and multi-organ damage. It is associated with respiratory and cardiological complications often leading patients to exitus. These conditions are also traditional risk factors for severe COVID-19. SARS-CoV-2 has affected people with chronic diseases, but the impact on people with Steinert's disease is poorly defined, with only a few reported and described. More data are needed to understand whether this genetic disease is a risk factor for more serious evolution or death in patients with COVID-19. Methodology: The study describes two cases of patients with SD and COVID-19 and summarizes available evidence of the clinical outcome of COVID-19 in patients with Steinert's disease, by performing a systematic review of the literature (following PRISMA statements and performing PROSPERO registration). Results: Overall, 5 cases were retrieved from the literature review, with a median age of 47 years, of whom 4 had advanced SD and unfortunately died. By contrast, the 2 patients from our clinical practice and 1 from literature had a good clinical outcomes. Mortality ranged from 57% (all cases) to 80% (only literature review). Conclusions: There is a high mortality rate in patients with both Steinert's disease and COVID-19. It highlights the importance of strengthening prevention strategies, especially vaccination. All SD with SARS-CoV-2 infection/COVID-19 patients should be identified early and treated to avoid complications. It is still unknown which treatment regimen is best to use in those patients. Studies on a greater number of patients are necessary to provide clinicians with further evidence. Competing Interests: No Conflict of Interest is declared (Copyright (c) 2023 Maria Mazzitelli, Marco Trevenzoli, Monica Brundu, Giulia Squarzoni, Anna Maria Cattelan.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|